China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use authorization (EUA) for its inhalable recombinant novel coronavirus vaccine (adenovirus type 5 vector) in Morocco. This marks a significant milestone in the global deployment of innovative COVID-19 vaccines.
Convidecia Profile
Convidecia, the recombinant novel coronavirus vaccine (adenovirus type 5 vector), was co-developed by CanSino Biologics and the China Academy of Military Medical Sciences. The vaccine obtained military special need drug approval in June 2020. Additionally, the inhalable recombinant COVID-19 vaccine (type 5 adenovirus vector) received clinical trial approval in China in March of this year. Convidecia became the first of its kind globally after gaining conditional approval from the National Medical Products Administration (NMPA) last month.
Global Impact and Future Prospects
The EUA in Morocco highlights the growing acceptance and deployment of innovative vaccination methods globally. CanSino Biologics continues to lead in the development and distribution of advanced vaccines, aiming to enhance global vaccination efforts and combat the ongoing pandemic.-Fineline Info & Tech
